Atea Pharmaceuticals (AVIR) Total Non-Current Liabilities (2019 - 2025)

Atea Pharmaceuticals' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $39.8 million for Q4 2025.

• In Q4 2025, Total Non-Current Liabilities rose 104.6% year-over-year to $39.8 million; the TTM figure through Dec 2025 stood at $39.8 million (up 104.6% YoY), while the FY2025 annual figure was $39.8 million, up 104.6% from the prior year.
• Total Non-Current Liabilities was $39.8 million for Q4 2025 at Atea Pharmaceuticals, up from $20.4 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $273.7 million in Q2 2021 to a low of $14.6 million in Q1 2023.
• Historically, Total Non-Current Liabilities has averaged $52.1 million across 5 years, with a median of $26.2 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities sank 89.81% in 2022, then surged 193.33% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $56.9 million in 2021, then slumped by 63.29% to $20.9 million in 2022, then soared by 62.91% to $34.0 million in 2023, then sank by 42.84% to $19.4 million in 2024, then jumped by 104.6% to $39.8 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $39.8 million (Q4 2025), $20.4 million (Q3 2025), and $20.5 million (Q2 2025), per Business Quant data.